ClinicalTrials.gg
CompletedNCT01637012ALEX OCTUpdated Mar 13, 2014

Prospective, Single-arm, Multicenter Study for Evaluation the Safety and Effectiveness of the ALEX Stent in a Real-world Setting of Percutaneous Coronary Interventions in Patients With Coronary Heart Disease

A Phase 4 interventional study of Implantation in Stable Angina, Unstable Angina and Myocardial Infarction, sponsored by Balton Sp.zo.o.. Completed at 5 sites in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-03-13.

Sponsored by Balton Sp.zo.o. · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

To evaluate the safety and effectiveness of the ALEX stent in a real-world setting of percutaneous coronary interventions in patients with coronary heart disease.

Read the detailed description

Prospective, multicenter, non-randomized study designed to enroll up to 60 subjects to evaluate the safety and effectiveness of the cobalt-chromium sirolimus eluting coronary stent ALEX in a real-world setting of percutaneous coronary interventions in patients with coronary heart disease.

02

Conditions studied

  • Stable Angina
  • Unstable Angina
  • Myocardial Infarction

Keywords

  • ALEX
  • coronary stent
  • cobalt-chromium
  • sirolimus
  • OCT
03

In context

Angina, Stable

344 studies on the registry are indexed under Angina, Stable; 56 are open to participants now.

This study's enrollment of 60 is below the median of 150 across 231 interventional studies indexed under Angina, Stable.

Browse Angina, Stable studies →

Lead sponsor

Balton Sp.zo.o. is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Clinical Inclusion Criteria:

  • > 18 years of age
  • Patient must provide written prior to procedure using a form that is approved by the local Ethics Committee
  • clinical diagnosis of Stable Angina, Unstable Angina or Myocardial Infarction without ST elevation (NSTEMI) or Myocardial Infarction with ST elevation provided the expiry of 72 hours of the onset of symptoms and stable clinical and hemodynamical condition the Patient with patent postinfarcion artery (TIMI 3) and indications for PCI and next stage of revascularization in the other vessels
  • earlier effective supply of others lesions in others vessels in case of multivessels disease
  • female of must have a negative pregnancy test within 7 days prior to enrolment and utilize reliable for 12 months after enrolment

Angiographic Inclusion Criteria

  • target lesion stentosis must be > 70% (visual estimate)
  • Patient eligible for PCI treatment with the ALEX stent system (vessel diameter in range of 2.5 to 4.0 mm and length of lesion that allows to cover a single stent with maximum length of 30 mm in visual evaluation)

Exclusion criteria

Exclusion Criteria:

Clinical Exclusion Criteria

  • anticipated inablility of the patient to comply with 12 months of antiplatelet treatment (e. g. elective non-cardiac surgery following stenting, drug intolerance etc.)
  • acute or chronic renal failure (serum creatinine > 2 mg%, \< 60 ml/min/1.73m2)
  • (LVEF) \< 40%
  • cardiogenic shock
  • short (\< 1 year)
  • any significant medical condition which in the investigator's opinion may interference with the Patient's optimal participation in the study
  • current participation in another drug or device clinical trail in which there no be reached the primary endpoint or which clinically interferences with trail's enpoints

Angiographic Exclusion Criteria

  • chronic total occlusion
  • calcified lesion which cannot be successfully dilated
  • location of lesions in the winding vessels where there is no possibility of OCT imaging
  • target stenosis located in venous or arterial bridge
  • unprotected left main coronary disease with > 50% stenosis
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    ALEX stent arm

    implantation of ALEX stent during index procedure

    Procedure: Implantation

Interventions

  • ProcedureImplantation

    index angioplasty with ALEX stent implatation

    Also known as: ALEX Stent

06

What researchers measure

Primary outcomes

  1. Assessment of stent strut coverage and parameters of restenosis

    Assessment of stent strut coverage and parameters of restenosis in coronary angiography (QCA - Late Lumen Loss) and in OCT (percent of neointimal volume) 12 months follow-up after the baseline procedure in group of first 20 patients

    Time frame: at 12 months follow-up

  2. Assessment of stent strut coverage and parameters of restenosis

    Assessment of stent strut coverage and parameters of restenosis in coronary angiography (QCA - Late Lumen Loss) and in OCT (percent of neointimal volume) 6 months follow-up after the baseline procedure in group of second 20 patients

    Time frame: at 6 months follow-up

  3. Assessment of stent strut coverage and parameters of restenosis

    Assessment of stent strut coverage and parameters of restenosis in coronary angiography (QCA - Late Lumen Loss) and in OCT (percent of neointimal volume) at 3 months follow-up after the baseline procedure in group of third 20 patients

    Time frame: at 3 months follow-up

Secondary outcomes

  1. Procedural success

    Procedural success during baseline PCI assessed in coronary angiography (QCA)

    Time frame: during index hospitalization

  2. Occurrence of stent thrombosis

    Occurrence of stent thrombosis at 30 days follow-up

    Time frame: at 30 days follow-up

  3. Occurrence of stent thrombosis

    Occurrence of stent thrombosis at 12 months follow-up

    Time frame: at 12 months follow-up

  4. Incidence of Major Adverse Cardiac Events

    Incidence of Major Adverse Cardiac Events (MACEs) at 30 days follow-up defined as death, myocardial infarction target lesion re-PTCA or target lesion bypass graft

    Time frame: at 30 days follow-up

  5. Incidence of Major Adverse Cardiac Events

    Incidence of Major Adverse Cardiac Events (MACEs) at 12 months follow-up defined as death, myocardial infarction target lesion re-PTCA or target lesion bypass graft

    Time frame: at 12 months follow-up

07

Study locations

5 sites
  • Carint Scanmed Szpital Sw. Rafala
    Krakow, Bochenka 12 30-693, Poland
  • Szpital Uniwersytecki w Krakowie, Samodzielna Pracownia Zakladu Hemodynamiki i Angiografii
    Krakow, Kopernika 17 31-501, Poland
  • Polsko-Amerykanskie Kliniki Serca I Oddzial Kardiologiczno-Angiologiczny
    Ustron, Sanatoryjna 7 43-450, Poland
  • Polsko-Amerykanskie Kliniki Serca III Oddzial Kardiologii Inwazyjnej, Angiologii i Elektrokardiologii
    Dabrowa Gornicza, Szpitalna 13 43-300, Poland
  • Centralny Szpital Kliniczny MSWiA w Warszawie Klinika Kardiologii Inwazyjnej
    Warszawa, Woloska 137 02-507, Poland
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2012
First posted
Jul 10, 2012
Start
Feb 2012
Primary completionActual
Sep 2013
CompletionActual
Sep 2013
Last update
Mar 13, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01637012
Lead sponsor
Balton Sp.zo.o.
Collaborators
KCRI
Responsible party
Sponsor
First posted
Jul 10, 2012
Start date
Feb 2012
Primary completion
Sep 2013
Completion
Sep 2013
Last update
Mar 13, 2014

Study contacts

Jacek Legutko, MD, PhD
principal investigator · Szpital Uniwersytecki w Krakowie, ul. Kopernika 17, Krakow 31-501, Poland
Dariusz Dudek, Prof.
study chair · Szpital Uniwersytecki w Krakowie, ul. Kopernika 17, Krakow 31-501, Poland

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion